OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis

Clinical Biochemistry

Volumn 39, Issue 6, 2006, Pages 617-622

  Wittersheim, Eric ^a   Mesquita, Maria ^a   Demulder, Anne ^a   Guns, Martine ^a   Louis, Olivia ^a   Melot, Christian ^b   Dratwa, Max ^a   Bergmann, Pierre ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Bone mineral density; End stage renal failure; Markers of bone turnover; OPG; RANK L; Renal osteodystrophy

Indexed keywords

COLLAGEN; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; TELOPEPTIDE;

ACROOSTEOLYSIS; ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RENAL OSTEODYSTROPHY; X RAY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE DENSITY; BONE REMODELING; CARRIER PROTEINS; FEMALE; GLYCOPROTEINS; HAND; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPROTEGERIN; PERITONEAL DIALYSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RENAL DIALYSIS;

EID: 33745455378     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.01.020     Document Type: Article

References (30)

1. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
2. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M., and Martin T. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
3. Huang J.C., Sakata T., Pfleger L.L., et al. PTH differentially regulates expression of RANKL and OPG. J. Bone Miner. Res. 19 (2004) 235-244
4. Goodman W.G., Cobrun J.W., Slatopolsky E., and Salusky I.B. Renal osteodystrophy in adults and children. In: Murray J.F. (Ed). Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed. (1999), Lippincott Williams and Wilkins Ed, Philadelphia, USA 341-360
5. Qi Q., Monier-Faugere M.C., Geng Z., and Malluche H. Predictive value of serum parathyroid hormone level for bone turnover in patients on chronic maintenance dialysis. Am. J. Kidney Dis. 26 (1995) 622-631
6. Avbersek-Luznik I., Malesic I., Rus I., and Marc J. Increased levels of osteoprotegerin in hemodialysis patients. J. Clin. Chem. Lab. Med. 40 (2002) 1019-1023
7. Coen G., Ballanti P., Balducci A., et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol. Dial Transplant. 17 (2002) 233-238
8. Haas M., Leko-Mohr Z., Roschger P., et al. Osteoprotegerin and parathyroid hormone as a marker of high turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am. J. Kidney Dis. 39 (2002) 580-586
9. Avbersek-Luznik I., Pecovnik Balon B., Rus I., and Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?. Nephrol. Dial Transplant. 20 (2005) 566-570
10. Chen D., Sarikaya N., Gunn H., et al. ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clin. Chem. 47 (2001) 747-749
11. Yano K., Tsuda E., Washida N., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14 (1999) 518-527
12. Reichel H., Roth H.J., and Schmidt-Gayk H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron, Clin. Pract. 98 (2004) 112-118
13. Melkko J., Niemi S., Risteli L., and Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36 (1990) 1328-1332
14. Ritz E., Prager P., Krempien B., Bommer J., Malluche H., and Schmidt-Gayk H. Skeletal X-ray findings and bone histology in patients on haemodialysis. Kidney Int. 13 (1978) 316-323
15. Kuhlencordt F., and Ringe J.D. Bone mineral content during chronic hemodialysis: long term observation by 125-i photonabsorptiometry (author's translation). Klin. Wochenschr. 56 (1978) 75-79
16. Lipton A., Ali S.M., Leitzel K., et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res. 8 (2002) 2306-2310
17. Szulc P., Hofbauer L., Heufelder A., et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J. Clin. Endocrinol. Metab. 86 (2001) 3162-3165
18. Kudlacek S., Schneider B., Woloszczuk W., et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32 (2003) 681-686
19. Khosla S., Arrighi H.M., Melton L.J., et al. Correlates of osteoprotegerin levels in women and men. Osteoporos. Int. 13 (2002) 394-399
20. Trofimov S., Pantsulaia I., Kobyliansky E., and Livshits G. Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. Eur. J. Endocrinol. 150 (2004) 305-311
21. Grzegorzewska A.E., and Mlot M. Serum osteoprotegrin level is lower in peritoneal dialysis patients than in hemodialysis ones. Rocz. Akad. Med. BiaLymst. 49 (2004) 193-196
22. Gonnelli S., Montagnani A., Caffarelli C., et al. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic haemodialysis. J. Endocrinol. Invest. 28 (2005) 534-539
23. Murray T.M., Rao L.G., and Rizzoli R.E. Interactions of parathyroid hormone, parathyroid hormone-related protein, and their fragments with conventional receptor sites. In: Bilezikian J.P. (Ed). The parathyroids, basic and clinical concepts (1994), Raven Press, Ltd., New York, USA 185-211
24. Mallette L.E. Parathyroid hormone and parathyroid hormone-related protein as polyhormones. In: Bilezikian J.P. (Ed). The parathyroids, basic and clinical concepts (1994), Raven Press, Ltd., New York, USA 171-184
25. Abrahamsen B., Hjelmborg J.V., Kostenuik P., et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 36 (2005) 727-735
26. Indridason O.S., Franzson L., and Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos. Int. 16 (2005) 417-423
27. Oh K.W., Rhee E.J., Lee W.Y., et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin. Endocrinol. (Oxf) 62 (2005) 92-98
28. Han K.O., Choi J.T., Choi H.A., et al. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin. Endocrinol. (Oxf) 62 (2005) 349-353
29. Rogers A., and Eastell R. Circulating osteoprotegerin (OPG) and receptor activator for NF-kB ligand (RANKL): clinical utility in metabolic bone disease assessment. J. Clin. Endocrinol. Metab. 90 (2005) 6323-6331
30. Mazzaferro S., Coen G., Ballanti P., et al. Osteocalcin, iPTH, Alkaline phosphatase and hand X-ray scores as predictive indices of histomorphometric parameters in renal osteodystrophy. Nephron 56 (1990) 261-266